NeoGenomics (NEO) Stock Price, News & Analysis

Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Key Stats

• Today's Range: $7.99 to $8.28
• 50-Day Range: $6.39 to $10.88
• 52-Week Range: $6.08 to $19.12
• Volume: 961,071 shs
• Average Volume: 1.11 million shs
• Market Capitalization: $1.04 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.83
• Consensus Rating: Moderate Buy

NeoGenomics Stock Analysis - MarketRank™

NeoGenomics scored higher than 77% of companies evaluated by MarketBeat, and ranked 219th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

NeoGenomics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to $0.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeoGenomics is -12.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeoGenomics is -12.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeoGenomics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.93% of the float of NeoGenomics has been sold short.

Short Interest Ratio / Days to Cover

NeoGenomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeoGenomics has recently increased by 2.89%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeoGenomics does not currently pay a dividend.

Dividend Growth

NeoGenomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.93% of the float of NeoGenomics has been sold short.

Short Interest Ratio / Days to Cover

NeoGenomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeoGenomics has recently increased by 2.89%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.28

News Sentiment

NeoGenomics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 24 news articles for NeoGenomics this week, compared to 5 articles on an average week.

Search Interest

16 people have searched for NEO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

4 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, NeoGenomics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $463,532.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.40% of the stock of NeoGenomics is held by insiders.

Percentage Held by Institutions

98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NEO Stock Analysis - Frequently Asked Questions

How have NEO shares performed this year?

NeoGenomics' stock was trading at $16.48 at the start of the year. Since then, NEO stock has decreased by 51.2% and is now trading at $8.05.
View the best growth stocks for 2025 here.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings results on Tuesday, April, 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.06. The firm's quarterly revenue was up 7.6% compared to the same quarter last year.
Read the conference call transcript.

Does NeoGenomics have any subsidiaries?

NeoGenomics subsidiaries include Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and more.

Who are NeoGenomics' major shareholders?

NeoGenomics' top institutional investors include Vanguard Group Inc. (11.08%), Brown Advisory Inc. (3.01%), Segall Bryant & Hamill LLC (1.83%) and Jennison Associates LLC (1.19%). Insiders that own company stock include Jeffrey Scott Sherman, Stephen M Kanovsky, Alicia C Olivo, Anthony P Zook and David Brian Perez.
View institutional ownership trends.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR) and AUO (AUOTY).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 5/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Testing laboratories
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:NEO
• CIK: 1077183
• Web: www.neogenomics.com
• Phone: (239) 768-0600
• Fax: 239-690-4237
• Employees: 2,100
• Year Founded: 2002

Price Target and Rating

• Average Stock Price Target: $13.83
• High Stock Price Target: $22.00
• Low Stock Price Target: $8.50
• Potential Upside/Downside: +71.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-87,970,000.00
• Net Margins: -11.92%
• Pretax Margin: -12.21%
• Return on Equity: -2.10%
• Return on Assets: -1.17%

Debt

• Debt-to-Equity Ratio: 0.38
• Current Ratio: 1.98
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: $672.36 million
• Price / Sales: 1.54
• Cash Flow: $0.30 per share
• Price / Cash Flow: 27.03
• Book Value: $7.02 per share
• Price / Book: 1.15

Miscellaneous

• Outstanding Shares: 128,695,000
• Free Float: 126,791,000
• Market Cap: $1.04 billion
• Optionable: Optionable
• Beta: 1.60